Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 694-700

  Hayashi, Mitsuhiro ^a,b   Okumura, Yasuhiro ^b   Osako, Tomofumi ^b   Toyozumi, Yasuo ^b   Arima, Nobuyuki ^b   Iwase, Hirotaka ^a   Nishimura, Reiki ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Human epidermal growth factor receptor 2; Metastatic breast cancer; p53 overexpression; Time to progression; Trastuzumab; Treatment beyond progression

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; MEDROXYPROGESTERONE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; JAPAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855207735     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0251-1     Document Type: Article

References (22)

1. CA Hudis 2007 Trastuzumab: mechanism of action and use in clinical practice N Engl J Med 357 39 51 17611206 10.1056/NEJMra043186 1:CAS:528:DC%2BD2sXnsVygu7s%3D (Pubitemid 47026733)
2. S Dawood K Broglio AU Buzdar, et al. 2010 Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 92 98 19933921 10.1200/JCO.2008.19. 9844 1:CAS:528:DC%2BC3cXhtF2rsr0%3D
3. M Marty F Cognetti D Maraninchi, et al. 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D (Pubitemid 46207001)
4. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
5. RJ Pietras MD Pegram RS Finn, et al. 1998 Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Oncogene 17 2235 2249 9811454 10.1038/sj.onc.1202132 1:CAS:528:DyaK1cXntlelu78%3D (Pubitemid 28515376)
6. KL Blackwell HJ Burstein AM Storniolo, et al. 2010 Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 1124 1130 20124187 10.1200/JCO.2008.21.4437 1:CAS:528:DC%2BC3cXktF2ltLo%3D
7. G von Minckwitz A du Bois M Schmidt, et al. 2009 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study J Clin Oncol 27 1999 2006 10.1200/JCO.2008.19.6618
8. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
9. M Scaltriti F Rojo A Ocana, et al. 2007 Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst 99 628 638 17440164 10.1093/jnci/djk134 1:CAS:528:DC%2BD2sXlvVSktr4%3D (Pubitemid 47073544)
10. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 15324695 10.1016/j.ccr.2004.06.022 1:CAS:528:DC%2BD2cXns1arsr8%3D (Pubitemid 39485684)
11. Y Lu X Zi Y Zhao, et al. 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 1852 1857 11752009 10.1093/jnci/93.24.1852 1:CAS:528:DC%2BD38XltVWluw%3D%3D (Pubitemid 34048651)
12. G Metro D Giannarelli D Gemma, et al. 2010 Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer Breast J 16 66 72 19889170 10.1111/j.1524-4741.2009.00849.x 1:CAS:528:DC%2BC3cXitVKhsL0%3D
13. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. K Kai R Nishimura N Arima, et al. 2006 p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study Int J Clin Oncol 11 426 433 17180510 10.1007/s10147-006-0601-6 1:CAS:528:DC%2BD28XhtlalurzJ (Pubitemid 44974395)
15. R Nishimura T Osako Y Okumura, et al. 2010 Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer Exp Ther Med 1 747 754 10.3892/etm.2010.133
16. MA Molina J Codony-Servat J Albanell, et al. 2001 Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res 61 4744 4749 11406546 1:CAS:528:DC%2BD3MXks1Grtbo%3D (Pubitemid 32691885)
17. M Hayashi K Kai Y Okumura, et al. 2011 Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy Oncol Lett 2 303 308 1:CAS:528:DC%2BC3MXjvFShtbc%3D
18. JM Extra EC Antoine A Vincent-Salomon, et al. 2010 Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study Oncologist 15 799 809 20671105 10.1634/theoncologist.2009-0029 1:CAS:528:DC%2BC3cXht1SqtbnM
19. M Scaltriti PJ Eichhorn J Cortes, et al. 2011 Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients Proc Natl Acad Sci USA 108 3761 3766 21321214 10.1073/pnas.1014835108 1:CAS:528:DC%2BC3MXivFOltLY%3D
20. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D (Pubitemid 34111379)
21. H Yamashita T Toyama M Nishio, et al. 2006 p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer Breast Cancer Res 8 R48 16869955 10.1186/bcr1536
22. SK Mohsin HL Weiss MC Gutierrez, et al. 2005 Neoadjuvant trastuzumab induces apoptosis in primary breast cancers J Clin Oncol 23 2460 2468 15710948 10.1200/JCO.2005.00.661 1:CAS:528:DC%2BD2MXjvVyktL4%3D (Pubitemid 47050836)